| 11.66 0.41 (3.64%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 19.15 | 1-year : | 22.37 |
| Resists | First : | 16.39 | Second : | 19.15 |
| Pivot price | 12.25  |
|||
| Supports | First : | 9.72 | Second : | 5.59 |
| MAs | MA(5) : | 11.57 |
MA(20) : | 12.54 |
| MA(100) : | 6.94 |
MA(250) : | 7.17 |
|
| MACD | MACD : | 0.7 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 16.2 |
D(3) : | 14.8 |
| RSI | RSI(14): 55.2 |
|||
| 52-week | High : | 16.39 | Low : | 3.34 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ STOK ] has closed above bottom band by 26.8%. Bollinger Bands are 17.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12.06 - 12.1 | 12.1 - 12.15 |
| Low: | 10.96 - 11.01 | 11.01 - 11.06 |
| Close: | 11.58 - 11.66 | 11.66 - 11.74 |
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Mon, 22 Apr 2024
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 4.4% - MarketBeat
Mon, 22 Apr 2024
Is a Surprise Coming for Stoke Therapeutics (STOK) This Earnings Season? - Yahoo Movies UK
Fri, 19 Apr 2024
Skorpios Trust sells $41.76 million of Stoke Therapeutics stock - Investing.com Nigeria
Thu, 18 Apr 2024
Stoke Therapeutics, Inc. (NASDAQ:STOK) Major Shareholder Sells $41,760,000.00 in Stock - MarketBeat
Wed, 17 Apr 2024
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer - Business Wire
Thu, 04 Apr 2024
Stoke Therapeutics Stock: Dravet Data Sends Shares Soaring One For Watchlist (NASDAQ:STOK) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 3.546e+007 (%) |
| Held by Institutions | 4.6 (%) |
| Shares Short | 3,760 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.123e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 55.8 % |
| Return on Equity (ttm) | -29.7 % |
| Qtrly Rev. Growth | 8.78e+006 % |
| Gross Profit (p.s.) | -18.82 |
| Sales Per Share | -80 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -81 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0.2 |
| Price to Book value | 0 |
| Price to Sales | -0.15 |
| Price to Cash Flow | 2.55 |
| Dividend | 0 |
| Forward Dividend | 4.95e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|